Is XLV a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The case for XLV is simple: low-cost, diversified exposure to Health Care Select Sector at a 0.08% expense ratio, anchored by names like LLY, UNH, JNJ. If that is the exposure you want and you do not already own most of it through another fund, XLV is a strong core holding. The catch is concentration in its top names and overlap with broad-market funds you may already hold. Whether it is a buy comes down to whether you want Health Care Select Sector and at what cost. Not a recommendation; Walnut is not an investment adviser.
What are you buying with XLV?
Tracks the healthcare sector of the S&P 500: large US pharmaceutical, biotech, managed-care, medical device, and life-science companies. A defensive sector tilt rather than a broad-market core, often less correlated with technology than the overall index. Verify current figures on the issuer's site.
Largest holdings (approximate as of early 2026; verify on State Street SPDR's fund page):
What's the case for XLV?
XLV is the Health Care Select Sector SPDR Fund, a fund that tracks the healthcare sector of the S&P 500 at a 0.08% expense ratio. It holds the large US pharma, biotech, insurer, device, and equipment companies (LLY, UNH, JNJ), so it is a sector bet on healthcare rather than a broad-market core. Versus VOO, XLV strips out everything except healthcare, which makes it more defensive and less tech-driven than the overall market.
In its favour: it gives you Health Care Select Sector exposure in one ticker at a 0.08% expense ratio, which is simple to hold and cheap to own.
What should you weigh before buying XLV?
- Cost vs alternatives: 0.08% is the fee; compare it to funds tracking a similar index.
- Concentration: check how much of XLV sits in its largest holdings (LLY, UNH, JNJ).
- Overlap: if you already own a broad-market fund, you may already hold much of this.
- Tracking scope: XLV only gives you Health Care Select Sector; it will not capture what sits outside that index.
How do you decide if XLV is a buy?
The useful question is rarely “will XLV go up?” It is “does this exposure fit my plan, at a cost I am happy with, without doubling up on what I already own?” Walnut connects your real brokerage so you can see exactly how XLV would overlap with your current holdings, analyze it by chatting through Claude or ChatGPT, and place any trade yourself. You stay in control.
The bottom line on XLV
The bottom line: XLV is a low-cost core building block for Health Care Select Sector exposure, not a tactical bet on a single name. If you want Health Care Select Sector exposure and the 0.08% fee is competitive for you, it does its job well. If you already own that exposure through another fund, adding it mostly doubles a fee without adding diversification. Decide from your goal and your existing holdings, not from where the market sat last week. Walnut is not an investment adviser.
More on XLV
- What is XLV? (holdings, cost, performance, and the themes it covers)
- XLV dividend: yield and schedule
Investing in XLV with AI
Connect the broker you already use and ask Walnut's AI how XLV fits what you actually hold: what it overlaps with, what it leaves you exposed to, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is XLV a good ETF to buy?
+
Walnut is informational, not investment advice. Whether XLV fits depends on your goals, time horizon, and what you already hold. It tracks Health Care Select Sector at a 0.08% expense ratio, so the questions that matter are whether you want that exposure, whether you already own it through another fund, and whether the cost is competitive for what it does.
What does XLV actually hold?
+
XLV tracks Health Care Select Sector. Its largest positions include LLY, UNH, JNJ, ABBV, MRK and others (approximate, verify on State Street SPDR's fund page). The holdings are what you are really buying, not the ticker.
What is XLV's expense ratio?
+
0.08% as of early 2026. Over decades, the expense ratio is one of the few things you can control, so it is worth comparing against close alternatives that track a similar index.
Does XLV pay a dividend?
+
XLV distributes a dividend with an approximate yield of ~1.6% (early 2026). See the XLV dividend page for how distributions work. Verify the current figure with State Street SPDR.
What are the risks of buying XLV?
+
Like any index ETF, weigh concentration (how much sits in the top holdings), overlap with funds you already own, and whether Health Care Select Sector matches the exposure you actually want. XLV only gives you Health Care Select Sector, not what sits outside it.
How do I decide if XLV is right for me?
+
Start from your goal, then check four things: what XLV holds, its cost versus alternatives, how much it overlaps with what you already own, and whether the exposure fits your time horizon and risk tolerance. Walnut can analyze the overlap against your real holdings; you keep your broker and approve any trade.
Walnut is informational, not investment advice. Figures are approximations stamped to early 2026; verify current data with State Street SPDR or your broker. Nothing here is a recommendation to buy, sell, or hold any security.